TITLE

Cholecystokinin C-45T polymorphism and smoking cessation in women

AUTHOR(S)
Ton, Thanh G.; Rossing, Mary Anne; Bowen, Deborah J.; Wilkerson, Hui-Wen; Farin, Federico M.
PUB. DATE
January 2007
SOURCE
Nicotine & Tobacco Research;Jan2007, Vol. 9 Issue 1, p147
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In view of the effect of cholecystokinin (CCK) on dopaminergic neurons in the mesolimbic “reward” pathway of the brain, its gene has been a focus in studies of dopamine-related conditions and behaviors, including smoking. We assessed the association between the CCK C-45T polymorphism and smoking cessation among women who participated in a randomized clinical trial of d,l-fenfluramine conducted in the Seattle area in 1993–1994. Several years later (Mdn = 3.3 years, range = 2.4–6.9 years), 593 women provided a biological specimen and updated information about smoking habits. We defined short-term quitting as not smoking for at least 7 days immediately preceding the final (12-month) clinical trial visit, and long-term quitting as not smoking for at least the 6-month interval before the later recontact. CCK C-45T was not associated with either short-term (relative risk [RR] associated with the presence of T allele = 0.9, 95% CI = 0.6–1.4) or long-term (RR = 1.0, 95% CI = 0.6–1.5) smoking cessation. Also, we observed no association of this polymorphism with smoking cessation in subgroups of women defined by age or body mass index. No clear differences were found in smoking cessation rates associated with the presence of the T allele among women treated with d,l-fenfluramine versus those randomized to placebo. Our results fail to support prior evidence of an association of the CCK C-45T polymorphism with the ability to quit smoking.
ACCESSION #
24078496

 

Related Articles

  • International Dosage Differences in Fluoxetine Clinical Trials. Patten, Scott; Cipriani, Andrea; Brambilla, Paolo; Nosè, Michela; Barbui, Corrado // Canadian Journal of Psychiatry;Jan2005, Vol. 50 Issue 1, p31 

    Objective: International differences are thought to exist in dosages used by clinicians treating mood disorders. This study examined international dosage differences in antidepressant clinical trials, using a database formed and maintained as a component of a Cochrane review of comparative...

  • Menthol cigarettes and health risks in Lung Health Study data. Murray, Robert P.; Connett, John E.; Skeans, Melissa A.; Tashkin, Donald P. // Nicotine & Tobacco Research;Jan2007, Vol. 9 Issue 1, p101 

    Whether menthol cigarettes confer a higher risk of death than plain cigarettes is not known. The Lung Health Study (LHS) enrolled 5,887 adult smokers in a clinical trial of smoking cessation and ipratropium in the prevention of chronic obstructive pulmonary disease. LHS participants have been...

  • BUPROPION FOR SMOKING CESSATION. Jackson, Eric A. // Journal of Family Practice;Feb1998, Vol. 46 Issue 2, p111 

    The article discusses research being done on the use of bupropion and placebo for smoking cessation, with reference to a study by R. D. Hurt, D. P. L. Sachs, E. D. Glover et al, which appeared in the 1997 issue of the "New England Journal of Medicine." The randomized, double-blind study...

  • The efficacy of vigorous-intensity exercise as an aid to smoking cessation in adults with elevated anxiety sensitivity: study protocol for a randomized controlled trial. J. Smits, Jasper A.; Zvolensky, Michael J.; Rosenfield, David; Marcus, Bess H.; Church, Timothy S.; Frierson, Georita M.; Powers, Mark B.; Otto, Michael W.; Davis, Michelle L.; DeBoer, Lindsey B.; Briceno, Nicole F. // Trials;2012, Vol. 13 Issue 1, p207 

    Background: Although cigarette smoking is a leading cause of death and disability in the United States (US), over 40 million adults in the US currently smoke. Quitting smoking is particularly difficult for smokers with certain types of psychological vulnerability. Researchers have frequently...

  • Evotec's MAO-B Inhibitor Fails in Phase II Trial.  // Bioworld Week;4/20/2009, Vol. 17 Issue 16, p4 

    The article reports on the result of the Phase II clinical trial of smoking cessation drug called EVT 302 that failed to show improvement in the quit rate of smokers, and reassesses the manufacturer Evotec AG plans to reassess the drug following further analysis. EVT 302, a monoamine oxidase B...

  • First clinical trial involving only Maori. Kumar, Rajesh // New Zealand Doctor;2/9/2005, p6 

    Reveals that the drug bupropion is an effective smoking cessation treatment for Maori people in New Zealand based on a clinical trial report published in the "Thorax" periodical. Research who led the clinical trial.

  • Menstrual Phase Effects on Smoking Cessation: A Pilot Feasibility Study. Carpenter, Matthew J.; Saladin, Michael E.; Leinbach, Ashley S.; Larowe, Steven D.; Upadhyaya, Himanshu P. // Journal of Women's Health (15409996);Mar2008, Vol. 17 Issue 2, p293 

    Background and Objectives: A growing body of research suggests that nicotine withdrawal and cigarette craving may vary across the menstrual cycle and that the luteal phase of the cycle may be associated with increases in each. This potential relationship suggests that careful timing of quit...

  • The "file drawer" phenomenon: suppressing clinical evidence.  // CMAJ: Canadian Medical Association Journal;2/17/2004, Vol. 170 Issue 4, p437 

    Discusses the state of the clinical trials in Canada as of February 2004. Reason most clinical trial results are never reported in the public domain; Concealment of unfavorable evidence in clinical trials of selective serotonin reuptake inhibitors in children; Issue on the Merck guidelines for...

  • Lessons learned from the STAR*D depression trial. Denninger, John W. // Patient Care;Mar2007, Vol. 41 Issue 3, p27 

    The article provides information on the Sequenced Treatment Alternatives to Relieve Depression clinical trial in the U.S. According to the author, the purpose of this trial was to assess the effectiveness of various sequential treatment options in patients with nonpsychotic major depressive...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics